Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4064341
Max Phase: Preclinical
Molecular Formula: C57H80F2N8O18P2
Molecular Weight: 1265.25
Molecule Type: Small molecule
Associated Items:
ID: ALA4064341
Max Phase: Preclinical
Molecular Formula: C57H80F2N8O18P2
Molecular Weight: 1265.25
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: [3H]c1ccc(C(F)(F)[C@@H](/C=C/[C@H]2CCC(=O)N2CCCCCCC(=O)OCC)OC(=O)Cc2ccc(COC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)Nc3ccc(COC(=O)NCCCC(O)(P(=O)(O)O)P(=O)(O)O)cc3)cc2)cc1
Standard InChI: InChI=1S/C57H80F2N8O18P2/c1-4-82-49(69)17-10-5-6-11-33-67-44(27-29-48(67)68)26-28-47(57(58,59)42-14-8-7-9-15-42)85-50(70)35-39-18-20-40(21-19-39)37-84-55(74)66-46(34-38(2)3)52(72)65-45(16-12-31-62-53(60)61)51(71)64-43-24-22-41(23-25-43)36-83-54(73)63-32-13-30-56(75,86(76,77)78)87(79,80)81/h7-9,14-15,18-26,28,38,44-47,75H,4-6,10-13,16-17,27,29-37H2,1-3H3,(H,63,73)(H,64,71)(H,65,72)(H,66,74)(H4,60,61,62)(H2,76,77,78)(H2,79,80,81)/b28-26+/t44-,45-,46-,47+/m0/s1/i7T
Standard InChI Key: YTHMUYCYKJVXFI-HKAHDNPJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1265.25 | Molecular Weight (Monoisotopic): 1264.5034 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Xie H, Chen G, Young RN.. (2017) Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis., 60 (16): [PMID:28699744] [10.1021/acs.jmedchem.6b00951] |
Source(1):